SPC3649 Multiple Dose Study in Healthy Volunteers

Santaris Pharma A/S30 enrolled

Overview

The purpose of this study is to investigate the safety and tolerability of SPC3649 given in multiple doses to healthy volunteers.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

5 weekly doses

5 weekly doses

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy volunteers: Males and postmenopausal females aged ≥ 18 to 60 years

PRA international

Zuidlaren, Netherlands

Number of subjects experiencing adverse events

Time frame: Up to 169 Days

Peak Plasma Concentration (Cmax) of SPC3649

Time frame: Up to 169 Days

Effect on total Cholesterol

Time frame: Up to 169 Days

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.